Charles Schwab
LBRX

Charles Schwab’s LB Pharmaceuticals LBRX Stock Holding History

Charles Schwab’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.34M Buy
195,486
+9,391
+5% +$276K ﹤0.01% 2362
2026
Q1 		$4.59M Buy
186,095
+8,479
+5% +$196K ﹤0.01% 2440
2025
Q4 		$3.95M Buy
+177,616
New +$3.1M ﹤0.01% 2553

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Charles Schwab's LBRX Position: Q2 2026 in Review

Charles Schwab increased its LB Pharmaceuticals (LBRX) stake by 5% in Q2 2026, buying an estimated $276K and bringing the position to 195,486 shares worth $6.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2362.

Charles Schwab first reported a position in LBRX in Q4 2025 and has held it in 3 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Charles Schwab held 195,486 shares of LB Pharmaceuticals worth $6.34M as of Q2 2026.
  • Charles Schwab bought 9,391 LB Pharmaceuticals shares in Q2 2026, an estimated $276K.
  • LB Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2362 holding.
  • Charles Schwab first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.